Cruciferous metabolite supplement
DIM
In a single-dose study of absorption-enhanced DIM, mean half-life was 2.6 to 4.5 hours across dose groups; the app's figure is 3.7 hours.1
DIM after one dose: 50% at ~3.7 h, 25% at 7.4 h, 12.5% at 11.1 h.
Drawn from the half-life in the app's model, ~3.7 h. The model's figures
- Compound
- DIM
- Symbol
- DIM
- Family
- Supplements
- Parts
- 14
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
DIM (3,3'-diindolylmethane) is a dimer of indole-3-carbinol, a compound formed from glucobrassicin in cruciferous vegetables such as cabbage, broccoli, cauliflower and Brussels sprouts.1 In a phase 1 trial of oral indole-3-carbinol in women, indole-3-carbinol itself was not detectable in plasma and DIM was the only detectable product derived from it.2 Most of the human trials described below used BioResponse DIM, an absorption-enhanced formulation, and not unformulated DIM powder.1,3,4 The authors of the tamoxifen trial write that there is "limited evidence of clinically relevant activity of DIM or long-term safety data of its regular use".3
The app grades the evidence for DIM as limited. The trials described below were supported by the US National Cancer Institute (Reed, Thomson, Gee), Cancer Research UK (Castañon) and, for the intravaginal trial (Ashrafian), a contract funded by the Ministry of Education and Science of the Russian Federation; BioResponse supplied the capsules in the Thomson and Castañon trials; in the intravaginal trial two authors report a salary from IlmixGroup, which manufactures the drug tested, one reports a patent relating to the manuscript's content, and one reports a salary from MiraxBioPharma, which took part in the drug's development.1,3,4,5,6 The one DailyMed label for a DIM-containing product that a search returned is a multi-ingredient capsule labelled as a dietary supplement.7
How it works
Sources in this part
The proposed mechanism concerns estrogen metabolism: the investigators who ran the DIM pharmacokinetic study write that ingestion of the precursor indole-3-carbinol "elicited changes in drug and estrogen metabolism consistent with proposed chemoprevention mechanisms".1 In that earlier indole-3-carbinol work, four weeks at 400 mg twice daily resulted in "marked induction of CYP1A2" and in a doubling of the urinary 2-hydroxyestrone to 16α-hydroxyestrone ratio; these were results for indole-3-carbinol, not for DIM itself.1 In primary cultures of human hepatocytes, a laboratory study reported that "DIM significantly increased the expression of CYP1A1 and CYP1A2 at the mRNA and protein levels" and also "directly inhibited catalytic activity of CYP1A1 and CYP3A4 and to a lesser extent CYP1A2".8 In the tamoxifen trial the authors describe 2-hydroxyestrone as a metabolite that binds the estrogen receptor alpha with high affinity but lacks the ability to induce transcriptional activity, and they note that a higher urinary 2-OHE1 to 16α-OHE1 ratio has been hypothesised to be anti-tumorigenic.3 The same authors state that direct evidence that changing this ratio alters breast cancer occurrence or outcomes is lacking.3 The urinary 2/16α-OHE1 ratio was the primary endpoint of the tamoxifen trial; the primary outcome was originally breast density and was changed to the ratio on Data Safety Monitoring Board advice because high rates of bilateral mastectomy challenged recruitment.3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~3.7 h
- Bioavailability
- 15%
- Typical dose
- 100–300 mg/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~3.7 h | Mean half-life of 3.7 ± 1.2 h at 100 mg (3 subjects), 3.0 ± 0.6 h at 150 mg (3), 2.6 ± 0.7 h at 200 mg (3) and 4.5 ± 1.4 h at 300 mg (6) in healthy adults given single doses of BioResponse DIM; 3.5 h in the one subject with detectable DIM at 50 mg1 |
| Half-life, other trial | ~3.7 h | The authors of a cervical trial give "about 3 h" as the typical plasma half-life of DIM from BioResponse DIM4 |
| Time to peak | ~2 h | Mean time to maximum concentration of 2.7 ± 0.6 h (100 mg), 1.8 ± 1.0 h (150 mg), 2.5 ± 1.3 h (200 mg) and 2.2 ± 1.1 h (300 mg); "tmax at approximately 2 h" after single doses of indole-3-carbinol, measured as plasma DIM1,2 |
| Bioavailability | 15% | No percentage is reported in these sources; the authors write that DIM "is poorly absorbed from the gastrointestinal tract" and that the BioResponse formulation "exhibits higher bioavailability than does crystalline DIM"1 |
| Time above detection | Duration 12 h | Plasma DIM fell below the limit of detection by 12 h at doses of 150 mg or less and by 24 h at all doses (50 to 300 mg)1 |
The single-dose study in healthy adults reported a mean peak concentration (Cmax) of 32 ng/mL at 100 mg, 104 ng/mL at 200 mg and 108 ng/mL at 300 mg.1 Its authors conclude that "increasing the dose to 300 mg did not result in an increase in Cmax", while stating that the mean AUC was a linear function of dose across the range tested.1 The summary at the head of that paper and its Table 3 give different mean AUC values for the 200 mg group (553 and 417 ± 441 h·ng/mL) and the 100 mg group (128 and 136 ± 8 h·ng/mL).1 The authors also report "marked inter-individual variability in Cmax and AUC for DIM" despite restrictive entry criteria, with no correlation to sex, age or body mass index.1
Human studies
The table lists five published trials of DIM; one of them used a vaginal suppository, not an oral capsule.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Reed and colleagues, Cancer Epidemiology, Biomarkers & Prevention 20081 | Single ascending dose, randomised, placebo in 1 of 4 per group; funded by the US National Cancer Institute1 | Healthy, non-smoking men and women aged 22 to 58, groups of four1 | Single oral BioResponse DIM doses of 50, 100, 150, 200 or 300 mg; sampled for 24 h1 | Mean Cmax 104 ng/mL at 200 mg and 108 ng/mL at 300 mg; DIM detectable in one subject only at 50 mg; adverse events grade I, vomiting after 300 mg judged probably related1 |
| Thomson and colleagues, Breast Cancer Research and Treatment 20173 | Randomised, double-blind, placebo-controlled; funded by the National Cancer Institute; capsules supplied by BioResponse3 | Women taking tamoxifen (n = 130 randomised); 98 completed3 | BioResponse DIM 150 mg twice daily or placebo for 12 months3 | Urinary 2/16α-OHE1 ratio up with DIM; SHBG up; no change in breast density or serum E1 and E2; plasma endoxifen, 4-OH tamoxifen and N-desmethyl-tamoxifen reduced; discoloured urine in 40% on DIM3 |
| Castañon and colleagues, British Journal of Cancer 20124 | Pragmatic, double-blind, randomised 2 DIM to 1 placebo; funded by Cancer Research UK; capsules supplied free by BioResponse4 | Women with newly diagnosed low-grade cervical cytological abnormalities; 603 randomised, 551 analysed4 | 150 mg DIM daily or placebo for 6 months4 | CIN2 or worse in 9% on DIM and 12% on placebo (RR 0.7, 95% CI 0.4 to 1.2); HPV-positive at 6 months among those positive at baseline 69% on DIM and 61% on placebo; urine darkening in 31% against 10%4 |
| Ashrafian and colleagues, EPMA Journal 20155 | Multicentre, randomised, placebo-controlled, double-blind, phase IIa; authors report ties to the manufacturer and a patent5 | 78 women of reproductive age with CIN I-II enrolled (26 per group); 21 (100 mg/day), 19 (200 mg/day) and 18 (placebo) in the 180-day efficacy analysis5 | Intravaginal DIM suppositories, 100 or 200 mg/day or placebo, up to 180 days5 | Absence of CIN in 90.5% (100 mg/day), 100.0% (200 mg/day) and 61.1% (placebo) of those analysed; adverse events in 40.0% (100 mg/day), 42.0% (200 mg/day) and 22% (placebo), a difference the authors call significant; no serious adverse events; 4 women excluded for safety reasons ahead of schedule; 6 withdrew consent before the first dose and 10 after therapy began; the authors note a small number of patients5 |
| Gee and colleagues, European Journal of Cancer Prevention 20166 | Multicentre, double-blind, placebo-controlled phase Ib; funded by the National Cancer Institute6 | 45 patients with organ-confined prostate cancer awaiting prostatectomy6 | BioResponse DIM 100 or 200 mg twice daily or placebo for 21 to 28 days6 | DIM detected in seven of 28 prostate tissue specimens; a statistically significant difference in the change in the urinary 2-hydroxyestrone/16-hydroxyestrone ratio between placebo and the 400 mg DIM group, with otherwise statistically nonsignificant changes in plasma biomarker expression; the authors report no consistent or significant tissue accumulation or biomarker modulation6 |
Deeper analysis: Thomson 2017, DIM with tamoxifen
Thomson and colleagues at the University of Arizona reported this randomised, double-blind, placebo-controlled trial in Breast Cancer Research and Treatment in 2017.3 Women were cancer-free, had been taking tamoxifen for at least 3 months, and were randomised 1:1 to BioResponse DIM or placebo twice daily; the mean age was 53.0 years and the mean time on tamoxifen was 1.7 years.3 Dosing began at 75 mg twice daily in the first 10 participants and, after review by the Data Safety and Monitoring Committee, rose to 150 mg twice daily for them and for all later enrollees.3 The primary endpoint was the change in the urinary 2/16α-OHE1 ratio; secondary measures were 4-hydroxyestrone, serum estrogens, SHBG, breast density and tamoxifen metabolites.3 The authors state the primary outcome was originally breast density and was changed to the urinary ratio, with Data Safety Monitoring Board advice, because high rates of bilateral mastectomy challenged recruitment.3 The registry entry lists the University of Arizona as lead sponsor with the National Cancer Institute as collaborator, the same urinary ratio as the primary outcome, and an actual enrolment of 144.9 Between March 2011 and October 2015, 156 women consented, 65 to each arm, and 98 women (51 placebo, 47 DIM) completed at least 12 months of study-assigned agent and a final study visit.3 The urinary 2/16α-OHE1 ratio increased with DIM (+3.2) and decreased with placebo (−0.7), P < 0.001, and serum SHBG rose by 25 ± 22 nmol/L with DIM against 1.1 ± 19 nmol/L with placebo.3 Null results were reported for breast density by mammography (n = 102 at baseline and 86 at 12 months) and by MRI (n = 73 and 60), and for serum E1 and E2.3 Plasma endoxifen (P < 0.001), 4-OH tamoxifen (P < 0.001) and N-desmethyl-tamoxifen (P = 0.001) were significantly lower with DIM, and the change in tamoxifen itself was not statistically significant (P = 0.06).3 The authors also report that treatment with DIM resulted in a greater number of women below the proposed therapeutic threshold of 5.6 ng/mL for endoxifen.3 The authors write that "the clinical significance of lowered levels of tamoxifen metabolites remains unclear", and call for research on whether these decreases attenuate "the clinical benefit of tamoxifen".3 Adverse events did not differ by arm except discoloured urine, reported by 40% of women on DIM; there were 14 reports of vaginal bleeding (6 on DIM, 8 on placebo), none leading to a cancer or hyperplasia diagnosis, and one placebo participant stopped tamoxifen and was removed from the study because of endometrial thickening.3 The stated target accrual for 95% power was 77 women per group, and the trial randomised 65 per arm.3 The authors name as limitations the inability "to assess the DIM effect on estrogen receptor target genes directly in breast tissue", limited generalisability beyond women taking tamoxifen, and that tamoxifen had been taken for an average of 1.7 years before enrolment, "limiting our ability to detect changes" in breast density.3 Funding came from the National Cancer Institute, including the University of Arizona cancer center support grant, and a research grant from the Academy of Nutrition and Dietetics, Oncology Nutrition Practice Group; BioResponse supplied the capsules, and the authors report no conflicts of interest.3
Deeper analysis: Reed 2008, single-dose pharmacokinetics
Reed and colleagues at the University of Kansas Medical Center reported a single ascending-dose study in Cancer Epidemiology, Biomarkers & Prevention in 2008, and the affiliation list includes the National Cancer Institute's Chemopreventive Agent Development Research Group.1 The study gave BioResponse DIM to drug-free, non-smoking healthy men and women in six groups of four (three on DIM and one on matching placebo), with fasting overnight and blood sampled from 0.5 to 24 hours.1 Only one subject at 50 mg had detectable DIM, and the values at 50 mg and in the 100, 150 and 200 mg groups rest on one or three subjects each.1 Adverse events were all classed as grade I; at 300 mg one of six subjects reported mild nausea and headache and one also reported vomiting, and the one adverse event judged probably related to DIM was the vomiting.1 The authors state that they cannot tell whether the lack of correspondence between DIM exposure and adverse effects reflects individual susceptibility or means that DIM did not cause those effects.1 The paper was supported by an NCI contract, and the capsules came from the National Cancer Institute's Division of Cancer Prevention.1
Deeper analysis: Castañon 2012, cervical cytology trial
Castañon and colleagues at the Wolfson Institute of Preventive Medicine, Queen Mary University of London, reported a pragmatic, double-blind trial in the British Journal of Cancer in 2012.4 Of the 551 randomised women available for analysis, CIN2 or worse occurred in 9% on DIM and 12% on placebo (risk ratio 0.7, 95% CI 0.4 to 1.2), and CIN3 or worse in 4.6% and 5.1% (RR 0.9, 95% CI 0.4 to 2.0).4 No sign of disease at 6 months occurred in 27.3% on DIM and 34.3% on placebo (RR 0.8, 95% CI 0.6 to 1.0).4 The authors concluded that short-term DIM at 150 mg a day "is unlikely to have an effect on cytology or HPV infection" and that "Uncertainty remains regarding its effect on CIN2+".4 A total of 10 serious adverse events were reported, 4 (1.0%) on DIM and 6 (3.0%) on placebo; three were reported as suspected unexpected serious adverse reactions, two of them in women on DIM, and darkening of urine was reported by 31% on DIM and 10% on placebo.4 Excluding urine darkening, 69% of women on DIM and 60% on placebo reported one or more non-serious adverse events (RR 1.2, 95% CI 1.0 to 1.3, P = 0.011), although no single adverse event other than urine darkening was reported significantly more often on DIM.4 The authors state that "the main limitation of this trial is the lack of power (only 30.3%) to address the primary endpoint owing to an insufficient number of women being recruited", and that 20% of women did not attend the 6-month appointment.4 A second stated limitation is that once-daily dosing "maybe sub-optimal" given the roughly 3 hour half-life of the formulation, and the women were likely heterogeneous in underlying histology because no baseline biopsy was taken.4 The trial was supported by Cancer Research UK grants, and BioResponse provided the DIM and placebo capsules without charge.4 The linked registry entry lists an estimated enrolment of 3000 and a completed status, against 603 women randomised in the publication.10,4
Other trials
Ashrafian and colleagues (EPMA Journal, 2015) tested intravaginal DIM suppositories in 78 women with CIN I-II; the authors write that the study "involved a small number of patients" and that the results "can only be considered preliminary" for choosing dose and duration.5 In that trial one author reports holding a patent relating to the manuscript's content.5 Because it used a vaginal suppository, its results are not taken as results for oral DIM.5 Gee and colleagues (European Journal of Cancer Prevention, 2016) reported that prostate tissue DIM was the primary endpoint, that DIM "was well tolerated", and a statistically significant difference in the change in the urinary 2-hydroxyestrone to 16-hydroxyestrone ratio between placebo and the 400 mg group, with otherwise statistically nonsignificant changes in plasma biomarker expression.6
Doses reported in studies and on labels
| Source | Setting | Dose, route and length |
|---|---|---|
| Reed 20081 | Healthy adults, single dose | Oral BioResponse DIM 50, 100, 150, 200 or 300 mg, once1 |
| Thomson 20173 | Women taking tamoxifen | Oral 150 mg twice daily for 12 months (started at 75 mg twice daily in the first 10 participants)3 |
| Castañon 20124 | Women with low-grade cervical cytology | Oral 150 mg daily for 6 months4 |
| Gee 20166 | Men with prostate cancer before prostatectomy | Oral 100 or 200 mg twice daily for 21 to 28 days6 |
| Ashrafian 20155 | Women with CIN I-II | Intravaginal suppository, 100 or 200 mg/day, up to 180 days5 |
| Tempo Balance US supplement label7 | Multi-ingredient capsule, not DIM alone | 150 mg DIM per capsule, with BioPerine 5 mg, broccoli extract 50 mg and calcium D-glucarate 50 mg; the label gives its suggested use as 1 capsule daily preferably with a meal or as directed by a healthcare professional7 |
The same label carries a caution for pregnant or nursing mothers, children under 18 and individuals with a known medical condition, naming consultation with a physician before using this or any dietary supplement.7
The app's typical range is 100 to 300 mg a day.
Side effects reported
Sources in this part
In the single-dose study, all adverse events were grade I, and one episode of vomiting at 300 mg was judged probably related to DIM.1 The same study lists flatulence in two subjects, one at 150 mg and one at 200 mg, and nausea and headache in one subject whose randomization code showed placebo.1 Reed and colleagues also cite a pilot study of 108 mg DIM daily for thirty days in 19 post-menopausal women, in which one reported a rash that resolved with discontinuing the supplement and taking antihistamines, two reported increased hot flashes but continued to take the supplement, and one complained of nausea when it was taken without food.1 In the 12-month tamoxifen trial, discoloured urine was the only adverse event that differed by arm, at 40% on DIM.3 In the 6-month cervical trial, darkening of urine was reported by 31% on DIM and 10% on placebo, and the authors say it is "due to a harmless by-product".4 That trial's authors note "anecdotal reports that DIM may increase the severity of migraine headaches" and report a non-significant difference in headaches (18% against 12%).4 In the intravaginal trial, adverse events were reported in 40.0% (100 mg/day) and 42.0% (200 mg/day) against 22% on placebo, a difference the authors describe as statistically significant, with no serious adverse events.5 In the same trial, four women stopped the study early because of adverse events: one on 200 mg/day (burning and itching in the vagina), two on 100 mg/day (burning and itching in the vagina; urticaria) and one on placebo (acute respiratory viral infection).5 Reed and colleagues refer to one published report of tumour promotion by DIM, in an aflatoxin B1-initiated liver tumour model in trout, and note that reports of promotion by indole-3-carbinol or DIM used high doses associated with toxicity.1 The tamoxifen trial reports that the lower tamoxifen metabolite levels with DIM were evident at 6 weeks.3
Bloodwork and markers
Sources in this part
The app lists E2, SHBG and liver enzymes as markers to monitor. In the tamoxifen trial, serum E1 and E2 did not differ by arm, and E2 analyses were limited to premenopausal women because 66% of postmenopausal women had values below detection limits.3 SHBG rose by 25 ± 22 nmol/L with DIM and by 1.1 ± 19 nmol/L with placebo, and the urinary 2/16α-OHE1 ratio rose, which the trial authors call a "favorable" change in estrogen metabolism.3 No liver enzyme result for DIM appears in the text of the tamoxifen trial or of the cervical trial; the tamoxifen trial excluded women with abnormal liver or renal function at entry.3,4 In the intravaginal trial, the authors report a group effect on plasma ALT (p = 0.034) and AST (p = 0.018), with lower values in the 200 mg/day group; increased plasma ALT and AST were also listed among the adverse events (2 events, both in the 200 mg/day group), and the authors write that to clarify the presence of hepatotoxicity they need further studies with a larger number of patients.5
Regulatory and anti-doping status
Sources in this part
A text search of the World Anti-Doping Agency's 2026 Prohibited List for "diindolylmethane" and "indol" returned no entry for DIM; the only match for "indol" was the unrelated substance pindolol.11 Classes such as S4.2 (anti-estrogenic substances) are headed "Including, but not limited to", so the search result is about named entries and is not a ruling on DIM.11 The one DailyMed label returned for DIM is a US dietary supplement label that carries the statement "These statements have not been evaluated by the Food and Drug Administration".7
Storage and handling
Sources in this part
The label for the one DIM-containing supplement found in DailyMed says "STORE IN A COOL, DRY PLACE".7
What is not known
Sources in this part
Bioavailability is not given as a percentage in the sources read, so the app's figure of 15% stands without a matching source figure, and the authors describe absorption as poor and formulation-dependent.1 Whether the lower plasma tamoxifen metabolites seen with DIM change the clinical benefit of tamoxifen is not known; the trial authors call for further research.3 Whether changing the urinary 2/16α-OHE1 ratio alters breast cancer outcomes is not established, according to the tamoxifen trial's authors.3 The longest intervention among the trials read was 12 months, and the authors of the tamoxifen trial write that there is limited evidence of long-term safety data for regular use of DIM.3 The oral cervical trial reported that its power to address its primary endpoint was only 30.3%, leaving the effect on CIN2 or worse uncertain.4 The app's notes describe the 3.7 hour half-life as derived from the single-dose study's AUC and Cmax, but that paper reports a mean half-life for each dose group in its Table 3 (2.6 to 4.5 hours), so the 3.7 hours matches a reported value for the 100 mg group.1 The app's notes say only one of four subjects had detectable DIM at 50 mg; in the paper each group had four subjects, of whom three received DIM, and one subject at 50 mg had detectable DIM.1
Frequently asked questions
What is the half-life of DIM?
In a single-dose study of healthy adults given BioResponse DIM, the mean half-life was 3.7 hours at 100 mg, 3.0 hours at 150 mg, 2.6 hours at 200 mg and 4.5 hours at 300 mg (3 subjects at 100, 150 and 200 mg, 6 at 300 mg), and the app's figure is 3.7 hours.1 The authors of a cervical trial describe the typical plasma half-life of BioResponse DIM as about 3 hours.4
How long does DIM take to reach its peak level?
Mean time to maximum concentration was 1.8 to 2.7 hours across single-dose groups in healthy adults, and the app's figure is about 2 hours.1
What is the bioavailability of DIM?
Is DIM the same as indole-3-carbinol?
Does DIM lower tamoxifen levels?
Does DIM change the 2/16 estrogen metabolite ratio?
Is DIM banned by WADA?
A text search of the 2026 WADA Prohibited List returned no entry for DIM.11
What side effects were reported in DIM trials?
In a 12-month trial, discoloured urine (40% on DIM) was the only adverse event that differed by arm; in a 6-month trial, darkening of urine was reported by 31% on DIM against 10% on placebo, and other non-serious adverse events were reported by 69% on DIM and 60% on placebo (RR 1.2, 95% CI 1.0 to 1.3, P = 0.011), although no single event other than urine darkening was reported significantly more often on DIM.3,4 In the single-dose study, vomiting after a 300 mg dose was judged probably related to DIM.1
Guides, tools and comparisons
References
- Reed GA, et al. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev 2008. PMID 18843002
- Reed GA, et al. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiol Biomarkers Prev 2006. PMID 17164373
- Thomson CA, et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Res Treat 2017. PMID 28560655
- Castañon A, et al. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. Br J Cancer 2012. PMID 22075942
- Ashrafian L, et al. Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane's efficacy and safety in the treatment of CIN. EPMA J 2015. PMID 26693258
- Gee JR, et al. Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev 2016. PMID 26313229
- Pronova Corporation. Tempo Balance (diindolylmethane, black pepper fruit extract, broccoli extract, calcium d-glucarate) capsule. US supplement label, DailyMed version 1, 5 May 2023. DailyMed label
- Gross-Steinmeyer K, et al. Modulation of aflatoxin B1-mediated genotoxicity in primary cultures of human hepatocytes by diindolylmethane, curcumin, and xanthohumols. Toxicol Sci 2009. PMID 19770484
- University of Arizona. Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer, ClinicalTrials.gov NCT01391689. NCT01391689
- Barts and the London School of Medicine and Dentistry. An Investigation Into the Effects of Diidolylmethane (BioResponse DIM) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1], ClinicalTrials.gov NCT00462813. NCT00462813
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list